Drugs not selected for Medicare price negotiation nearly doubled - report
The list prices of the top 25 drugs with the highest Medicare Part D spend that are not subject to drug price negotiations ...
Expanded research on COPD and metabolic syndrome would advance patient-centered care, expert argues
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
News Medical on MSN17h
Addressing COPD and metabolic syndrome requires comprehensive research efforts
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
Drugs not selected for Medicare negotiations saw prices nearly double - report
Top Medicare Part D drugs without price negotiations have seen a 98% increase in list prices since their launch. Read more ...
AARP21h
25 Top Medicare Part D Drugs Have Nearly Doubled in Price
People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...
New AARP Report: Top Medicare Part D Drugs See Average Lifetime Price Hike of 98%
List prices for the 25 top Medicare Part D drugs not currently selected for Medicare drug price negotiation have increased by an average of 98 percent—or nearly doubled—since they first entered the ...
Lupin gets USFDA nod for generic cystic fibrosis treatment medicine
India has the potential to increase exports of organic products up to Rs 20,000 crore in the next three years, Commerce and ...